|
Breakfast Symposia Programming
Monday, March 10
7:00 – 8:45 a.m.
Breakfast Symposium:
Community-Associated MRSA Infections—The Global Threat
Supported by an unrestricted educational grant from Cubist Pharmaceuticals
Hyatt Regency Phoenix
ACPE # 207-999-08-156-L04-P
VNA Approver Number:
Pharmacy & Nursing Continuing Education Contact Hours: 1.5
Session Summary:
Methicillin-resistant Staph aureus (MRSA) has emerged in the community with clinical, epidemiologic and bacteriologic characteristics distinct from healthcare associated MRSA. Community-Associated MRSA (CA-MRSA) infections are fast becoming common in the general population, requiring a change in therapeutic approach. Gather with colleagues to acquire the vital information essential for clinicians to have when making appropriate recommendations for the most effective therapy.
Faculty: Seth David Rosenbaum, MD Medical Specialty Associates, Infectious Diseases, Cherry Hill, NJ
Educational Objectives:
- Discuss the epidemiology of the emergence of methicillin resistance among hospital acquired S. aureus strains.
- Describe the history of the emergence of MRSA acquired in the Community (CA-MRSA).
- List five risk factors for CA-MRSA.
- Discuss the virulence factors associated with CA-MRSA that contribute to its pathological potential.
- Compare and contrast treatment options for suspected and documented CA-MRSA infections.
Breakfast Symposium:
Pharmacy and Nursing Considerations for Patients receiving Anti-TNF therapies in the Alternate-Site Setting
Supported by an unrestricted educational grant from Centocor, Inc.
Hyatt Regency Phoenix
ACPE# 207-999-08-157-L01-P
VNA Approver Number:
Pharmacy & Nursing Continuing Education Contact Hours: 1.5
Session Summary:
Treatment of autoimmune diseases, such as rheumatoid arthritis (RA), has been significantly enhanced through new medications termed anti-tumor necrosis factor (anti-TNF) therapies. TNF is made by blood cells known as cytokines, which are involved in the inflammatory process—and too much TNF causes an inflammatory response. In autoimmune disorders, this response can produce painful symptoms for those with diseases such as RA, psoriasis, Crohn’s disease and ulcerative colitis. Be present to obtain an in-depth review of new treatment considerations for patients receiving these anti-TNF therapies in the home and ambulatory infusion settings—including information on dosing, adverse drug reactions, administration guidelines and patient education.
Faculty: Grace Leone, RN, GHL Consulting
Educational Objectives:
- Identify the pathogenesis of immune mediated disorders treated with anti-tumor necrosis factor (anti-TNF) therapies.
- Explain the mechanism of action of anti-TNF therapies.
- Evaluate the effectiveness of a particular anti-TNF therapy and be able to make recommendations based on patient specific data.
- Describe the safety, dosing, and administration of anti-TNF therapies in the alternate-site setting.
- Use patient education tools to assist patients in choosing appropriate therapies.
Tuesday, March 11
7:00 – 8:45 a.m.
Breakfast Symposium:
Maximizing Antimicrobial Pharmacodynamics in the Treatment of Resistant Gram-negative Infections
Supported by an unrestricted educational grant from AstraZeneca
Hyatt Regency Phoenix
ACPE # 207-999-08-198-L04-P
VNA Approver Number:
Pharmacy & Nursing Continuing Education Contact Hours: 1.5
Session Summary:
There is an increasing number of patients being discharged from hospitals with nosocomial infections attributed to multiresistant gram-positive and gram-negative pathogens. Pharmacists and nurses caring for patients in the alternate-site infusion setting are increasingly involved in managing these infections after hospital discharge. In the last several years a number of novel antibiotics and treatment regimens have been developed. This program is designed to specifically address the treatment of resistant gram negative infections and highlight examples of the application of pharmacodynamic principles to maximize treatment outcomes.
Faculty: David Nicolau, PharmD, FCCP, Director for the Center for Anti-Infective Research and Development and Coordinator for Research in the Department of Medicine, Division of Infectious Diseases and Pharmacy, Hartford Hospital in Hartford, Connecticut
Educational Objectives:
- Describe the current status of antimicrobial resistance rates among predominant gram-negative pathogens.
- Describe changing epidemiology of resistant infections and factors contributing to these changes.
- Identify strategies to manage these infections and minimize the development of resistance.
- Discuss the susceptibility of bacterial pathogens to carbapenems and other broad-spectrum agents.
- Employ pharmacokinetic and pharmacodynamic principles to provide optimum outcomes when using meropenum in the alternate-site setting.
Breakfast Symposium:
Diagnosis and Treatment of Immune-Mediated Neuropathies
Supported by an unrestricted educational grant from Talecris Biotherapeutics
Hyatt Regency Phoenix
ACPE # 207-999-08-167-L01-P
VNA Approver Number:
Pharmacy & Nursing Continuing Education Contact Hours: 1.5
Session Summary:
Pharmacists and nurses practicing in the alternate-site setting often encounter patients being treated for immune-meditated neuropathies. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) are examples of neurological diseases treated with intravenous therapies. Join us to explore the current definition, diagnosis and treatment guidelines for immune-mediated neuropathies—and discuss specific regulatory and reimbursement issues related to such treatment approaches.
Faculty: Carol Lee Koski, MD, Medical Director, GBS/CIPD Foundation International, Baltimore, MD
Educational Objectives:
- Describe the clinical and laboratory diagnostic criteria for immune-mediated neuropathies treated in the alternate-site setting.
- Describe the immunopathologic mechanisms underlying immune-meditated neuropathies.
- Compare and contrast results of clinical trials exploring treatment approaches for immune-mediated neuropathies.
- Describe the anti-infective, anti-inflammatory and immunomodulatory mechanisms of action of IVIG.
- Discuss the regulatory and reimbursement issues related to treating patients with neurological diseases with IVIG in the alternate-site setting.
Wednesday, March 12
7:00 – 8:45 a.m.
Breakfast Symposium:
USP <797>: New Requirements for Compounding Sterile Preparations
Supported by an unrestricted educational grant from Hospira Worldwide, Inc.
Hyatt Regency Phoenix
ACPE #207-999-08-181-L01-P
VNA Approver Number:
Pharmacy & Nursing Continuing Education Contact Hours: 1.5
Session Summary:
Always an exceptionally “hot topic” in our field, this symposium will be presented by members of the USP Sterile Compounding Expert Committee and will offer a thorough review of the current status of regulations affecting sterile compounding—including an update on USP Chapter <797> revisions, as well as USP’s role in standards of practice. Come and learn about the implications of USP Chapter <797> changes for pharmacy organizations compounding sterile preparations.
Faculty: Eric Kastango, MBA, RPh, FASHP, President & CEO, Clinical IQ, LLC, Florham Park, NJ, and Donald Filibeck, PharmD, MBA, National Director, Pharmacy Services, Critical Care Systems, Nashua, NH
Educational Objectives:
- Explain the USP revision process and the ongoing role of USP in standards of practice.
- Summarize key changes proposed for the next USP <797> and their implications.
- Review the USP Chapters: contamination risk levels, personnel cleansing garbing and gloving, primary and secondary engineering controls, environmental monitoring, and cleaning and disinfection.
- Explain the evidence-based science behind the proposed changes in USP <797>.
- Describe plans for the future for USP <797>.
|
